Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study.
Temesgen Z, Assi M, Shweta FNU, Vergidis P, Rizza SA, Bauer PR, Pickering BW, Razonable RR, Libertin CR, Burger CD, Orenstein R, Vargas HE, Palraj R, Dababneh AS, Chappell G, Chappell D, Ahmed O, Sakemura R, Durrant C, Kenderian SS, Badley AD. Temesgen Z, et al. Among authors: durrant c. Mayo Clin Proc. 2020 Nov;95(11):2382-2394. doi: 10.1016/j.mayocp.2020.08.038. Epub 2020 Sep 3. Mayo Clin Proc. 2020. PMID: 33153629 Free PMC article.
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.
Temesgen Z, Burger CD, Baker J, Polk C, Libertin CR, Kelley CF, Marconi VC, Orenstein R, Catterson VM, Aronstein WS, Durrant C, Chappell D, Ahmed O, Chappell G, Badley AD; LIVE-AIR Study Group. Temesgen Z, et al. Among authors: durrant c. Lancet Respir Med. 2022 Mar;10(3):237-246. doi: 10.1016/S2213-2600(21)00494-X. Epub 2021 Dec 1. Lancet Respir Med. 2022. PMID: 34863332 Free PMC article. Clinical Trial.
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ, Walters DK, Ahmed O, Chappell D, Sahmoud T, Durrant C, Nevala WK, Patnaik MM, Pease LR, Hedin KE, Kay NE, Johnson AJ, Kenderian SS. Sterner RM, et al. Among authors: durrant c. Blood. 2019 Feb 14;133(7):697-709. doi: 10.1182/blood-2018-10-881722. Epub 2018 Nov 21. Blood. 2019. PMID: 30463995 Free PMC article.
First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 Pneumonia.
Temesgen Z, Assi M, Vergidis P, Rizza SA, Bauer PR, Pickering BW, Razonable RR, Libertin CR, Burger CD, Orenstein R, Vargas HE, Varatharaj Palraj BR, Dababneh AS, Chappell G, Chappell D, Ahmed O, Sakemura R, Durrant C, Kenderian SS, Badley A. Temesgen Z, et al. Among authors: durrant c. medRxiv [Preprint]. 2020 Jun 14:2020.06.08.20125369. doi: 10.1101/2020.06.08.20125369. medRxiv. 2020. PMID: 32587983 Free PMC article. Updated. Preprint.
GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity.
Cox MJ, Manriquez Roman C, Tapper EE, Siegler EL, Chappell D, Durrant C, Ahmed O, Sinha S, Mwangi R, Scott NS, Hefazi M, Schick KJ, Horvei P, Ruff MW, Can I, Adada M, Bezerra E, Kankeu Fonkoua LA, Parikh SA, Kay NE, Sakemura R, Kenderian SS. Cox MJ, et al. Among authors: durrant c. Leukemia. 2022 Jun;36(6):1635-1645. doi: 10.1038/s41375-022-01572-7. Epub 2022 Apr 19. Leukemia. 2022. PMID: 35440691 Free PMC article.
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial.
Temesgen Z, Kelley CF, Cerasoli F, Kilcoyne A, Chappell D, Durrant C, Ahmed O, Chappell G, Catterson V, Polk C, Badley A, Marconi VC; LIVE-AIR Study Group. Temesgen Z, et al. Among authors: durrant c. Thorax. 2023 Jun;78(6):606-616. doi: 10.1136/thoraxjnl-2022-218744. Epub 2022 Jul 6. Thorax. 2023. PMID: 35793833 Free PMC article. Clinical Trial.
Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia.
Patnaik MM, Sallman DA, Mangaonkar AA, Heuer R, Hirvela J, Zblewski D, Al-Kali A, Binder M, Balasis ME, Newman H, Letson C, Kruer TL, Gangat N, Komrokji RS, Tefferi A, Lo A, Shih T, Durrant C, List AF, Padron E. Patnaik MM, et al. Among authors: durrant c. Blood. 2020 Aug 13;136(7):909-913. doi: 10.1182/blood.2019004352. Blood. 2020. PMID: 32294158 Free PMC article. Clinical Trial. No abstract available.
Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer's disease.
Colom-Cadena M, Toombs J, Simzer E, Holt K, McGeachan R, Tulloch J, Jackson RJ, Catterson JH, Spires-Jones MP, Rose J, Waybright L, Caggiano AO, King D, Gobbo F, Davies C, Hooley M, Dunnett S, Tempelaar R, Meftah S, Tzioras M, Hamby ME, Izzo NJ, Catalano SM, Durrant CS, Smith C, Dando O, Spires-Jones TL. Colom-Cadena M, et al. Among authors: durrant cs. Acta Neuropathol. 2024 Feb 6;147(1):32. doi: 10.1007/s00401-023-02679-6. Acta Neuropathol. 2024. PMID: 38319380 Free PMC article.
p-tau Ser356 is associated with Alzheimer's disease pathology and is lowered in brain slice cultures using the NUAK inhibitor WZ4003.
Taylor LW, Simzer EM, Pimblett C, Lacey-Solymar OTT, McGeachan RI, Meftah S, Rose JL, Spires-Jones MP, Holt K, Catterson JH, Koch H, Liaquat I, Clarke JH, Skidmore J, Smith C, Booker SA, Brennan PM, Spires-Jones TL, Durrant CS. Taylor LW, et al. Among authors: durrant cs. Acta Neuropathol. 2024 Jan 4;147(1):7. doi: 10.1007/s00401-023-02667-w. Acta Neuropathol. 2024. PMID: 38175261 Free PMC article.
Protein retention in the endoplasmic reticulum rescues Aβ toxicity in Drosophila.
Catterson JH, Minkley L, Aspe S, Judd-Mole S, Moura S, Dyson MC, Rajasingam A, Woodling NS, Atilano ML, Ahmad M, Durrant CS, Spires-Jones TL, Partridge L. Catterson JH, et al. Among authors: durrant cs. Neurobiol Aging. 2023 Dec;132:154-174. doi: 10.1016/j.neurobiolaging.2023.09.008. Epub 2023 Sep 21. Neurobiol Aging. 2023. PMID: 37837732 Free PMC article.
129 results